Moving forward in myeloma research

Haematologica

Volumn 89, Issue 5, 2004, Pages 517-519

  Bladé, Joan ^a   Rosiñol, Laura ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; M PROTEIN; THALIDOMIDE;

CANCER SURVIVAL; CLINICAL RESEARCH; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; MYELOMA; PLASMA CELL; PROGNOSIS; STEM CELL TRANSPLANTATION;

BIOMEDICAL RESEARCH; HUMANS; MULTIPLE MYELOMA;

EID: 2542469757     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (24)

1. Bladé J, Vesole DH, Gertz MA. Transplantation for multiple myeloma: who, when, how often? Blood 2003;102:3469-77.
2. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000;95:4008-10.
3. Moreau P, Robilland N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than CD45 positive multiple myeloma. Haematologica 2004;89:37-41.
4. Asosingh K, Menu E, van Valckenborg E, van de Broek I, van Riet I, van Camp B, et al. Mechanisms involved in the differential bone marrow homing CD45 subsets in 5T murine models of myeloma. Clin Exp Metast 2002;19:583-91.
5. Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivates. J Clin Oncol 2003;21:4444-54.
6. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-9.
7. Weber D, Rankin K, Gavino, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
8. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin 1 and tumor necrosis factor-α in human multiple myeloma. Br J Haematol 1990;74:424-41.
9. Corral LG, Haslett PA, Muller GW, Chen R, Wong IM, Ocampo CJ, et al. Differential cytokine modulation and T-cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 1999;163:380-6.
10. Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson II, Romundstad P, et al. Low serum levels of soluble tumor necrosis factor receptor p55 predicst response to thalidomide in advanced multiple myeloma. Haematologica 2004;89:48-52.
11. Neben K, Mochler T, Egerer G, Kraemer A, Hillengass J, Benner A, et al. High plasma basic fibroblastic growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001;7:2675-81.
12. Thompson MA, Witzig TE, Kumar S, Timm, Haug J, Fonseca R, et al. Plasma levels of tumor necrosis factor α and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. Br J Haematol 2003;123:305-8.
13. Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. Cytokine 2004 (in press).
14. Bladé J, Esteve J, Rosiñol L, Perales M, Montoto S, Tuset M, et al. Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001;28:588-92.
15. Bladé J, Esteve J, Rives S, Martinez C, Rovira M, Urbano Ispizua, et al. High-dose therapy autotransplantation/intensification vs. continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transpl 2000;26:845-9.
16. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037-43.
17. Fenk R, Ak M, Kobbe G, Steidl U, Arnold C, Korthals M, et al. Quantitative molecular monitoring of minimal residual disease heralds relapse in patients with multiple myeloma. Haematologica 2004;89:53-62.
18. Nadal E, Giné E, Bladé J, Esteve J, Rosiñol L, Fernández-Avilés F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant 2004;33:61-4.
19. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Minimal residual disease monitoring in multiple myeloma. Best Prac Res Clin Haematol 2002;15:197-222.
20. San Miguel JF, Almeida J, Mateo G, Bladé J, López-Berges C, Caballero D, et al. Immunophenotype evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002;99:1853-6.
21. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-42.
22. Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, et al. Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 2000;109:24-9.
23. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004;89:63-73.
24. Bladé J, Rozman C, Montserrat E, Cervantes F, Felíu E, Grañena A, et al. Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). Eur J Cancer Clin Oncol 1986;10:1193-7.